Use of FK 506 in pediatric patients.

PK 506 is an immunosuppressive drug that holds par· ticular promise for pediatric patients because of its potency. relatively low toxicity. and simplicity of administration.1.2 Above all advantages is elimination of the need for adjuvant steroid therapy in the majority of cases. It was introduced for clinical trials in pediatric patients in September 1989. We report here our total experience with FK 506 in pediatric recipients of com· monly transplanted organs up to May I. 1990 with fol· low-up to August I. 1990. In addition. experience with new applications of FK 506 is included. A total of 74 pediatric patients were treated for the diverse indications summa· rized in Tables 1 to 4.